Krystal Net Debt vs Cash And Short Term Investments Analysis

KRYS Stock  USD 178.98  0.21  0.12%   
Krystal Biotech financial indicator trend analysis is infinitely more than just investigating Krystal Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Krystal Biotech is a good investment. Please check the relationship between Krystal Biotech Net Debt and its Cash And Short Term Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Net Debt vs Cash And Short Term Investments

Net Debt vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Krystal Biotech Net Debt account and Cash And Short Term Investments. At this time, the significance of the direction appears to have pay attention.
The correlation between Krystal Biotech's Net Debt and Cash And Short Term Investments is -0.92. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Krystal Biotech, assuming nothing else is changed. The correlation between historical values of Krystal Biotech's Net Debt and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Krystal Biotech are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Net Debt i.e., Krystal Biotech's Net Debt and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

-0.92
Relationship DirectionNegative 
Relationship StrengthSignificant

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Krystal Biotech balance sheet. This account contains Krystal Biotech investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Krystal Biotech fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Krystal Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 2.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 3.24 in 2024.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization2.8M4.1M5.0M5.3M
Interest Income197K5.2M22.6M23.8M

Krystal Biotech fundamental ratios Correlations

0.810.840.991.00.770.990.96-0.93-0.950.810.860.980.920.9-0.730.820.990.980.990.980.971.00.97-0.950.93
0.810.570.850.810.760.850.76-0.85-0.770.740.860.730.860.88-0.380.740.840.850.80.840.750.830.73-0.860.81
0.840.570.850.840.560.780.9-0.62-0.930.440.520.870.680.7-0.80.640.820.840.870.840.910.820.92-0.740.73
0.990.850.850.980.730.980.98-0.89-0.970.810.830.980.910.91-0.680.860.990.980.991.00.980.980.98-0.970.93
1.00.810.840.980.770.990.96-0.93-0.950.80.870.980.920.9-0.730.820.990.980.990.980.961.00.97-0.950.93
0.770.760.560.730.770.80.67-0.85-0.690.620.830.660.80.82-0.450.480.780.760.740.70.660.810.66-0.760.71
0.990.850.780.980.990.80.96-0.94-0.940.870.890.960.950.94-0.630.861.00.970.980.980.950.990.95-0.980.95
0.960.760.90.980.960.670.96-0.81-0.990.780.750.990.870.87-0.680.870.970.940.980.981.00.941.0-0.950.91
-0.93-0.85-0.62-0.89-0.93-0.85-0.94-0.810.8-0.81-0.97-0.85-0.92-0.910.6-0.73-0.92-0.93-0.9-0.88-0.81-0.95-0.810.89-0.89
-0.95-0.77-0.93-0.97-0.95-0.69-0.94-0.990.8-0.72-0.74-0.96-0.88-0.890.66-0.86-0.96-0.94-0.97-0.97-0.99-0.93-0.990.94-0.91
0.810.740.440.810.80.620.870.78-0.81-0.720.840.810.880.82-0.270.860.840.740.780.820.770.790.75-0.90.87
0.860.860.520.830.870.830.890.75-0.97-0.740.840.780.960.93-0.410.760.870.870.830.830.740.890.74-0.870.91
0.980.730.870.980.980.660.960.99-0.85-0.960.810.780.880.85-0.720.850.980.940.980.980.990.960.99-0.940.92
0.920.860.680.910.920.80.950.87-0.92-0.880.880.960.880.98-0.430.880.940.910.910.910.870.930.86-0.950.98
0.90.880.70.910.90.820.940.87-0.91-0.890.820.930.850.98-0.420.870.930.910.90.90.860.920.85-0.950.95
-0.73-0.38-0.8-0.68-0.73-0.45-0.63-0.680.60.66-0.27-0.41-0.72-0.43-0.42-0.32-0.66-0.74-0.73-0.67-0.69-0.72-0.730.51-0.48
0.820.740.640.860.820.480.860.87-0.73-0.860.860.760.850.880.87-0.320.860.810.850.880.870.80.84-0.910.92
0.990.840.820.990.990.781.00.97-0.92-0.960.840.870.980.940.93-0.660.860.980.990.990.970.990.97-0.980.94
0.980.850.840.980.980.760.970.94-0.93-0.940.740.870.940.910.91-0.740.810.980.980.970.940.990.95-0.930.91
0.990.80.870.990.990.740.980.98-0.9-0.970.780.830.980.910.9-0.730.850.990.980.990.980.990.98-0.950.93
0.980.840.841.00.980.70.980.98-0.88-0.970.820.830.980.910.9-0.670.880.990.970.990.980.970.98-0.970.94
0.970.750.910.980.960.660.951.0-0.81-0.990.770.740.990.870.86-0.690.870.970.940.980.980.941.0-0.940.91
1.00.830.820.981.00.810.990.94-0.95-0.930.790.890.960.930.92-0.720.80.990.990.990.970.940.95-0.950.93
0.970.730.920.980.970.660.951.0-0.81-0.990.750.740.990.860.85-0.730.840.970.950.980.981.00.95-0.930.9
-0.95-0.86-0.74-0.97-0.95-0.76-0.98-0.950.890.94-0.9-0.87-0.94-0.95-0.950.51-0.91-0.98-0.93-0.95-0.97-0.94-0.95-0.93-0.95
0.930.810.730.930.930.710.950.91-0.89-0.910.870.910.920.980.95-0.480.920.940.910.930.940.910.930.9-0.95
Click cells to compare fundamentals

Krystal Biotech Account Relationship Matchups

Krystal Biotech fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets209.0M310.8M626.3M558.5M818.4M859.3M
Other Current Liab19K26K87K23.3M27.5M28.9M
Total Current Liabilities3.3M15.5M25.7M28.8M33.1M34.7M
Total Stockholder Equity202.9M292.1M593.6M522.2M778.6M817.6M
Net Tangible Assets202.9M292.1M593.6M522.2M600.6M630.6M
Property Plant And Equipment Net11.2M34.2M119.6M169.7M168.2M176.6M
Net Debt(184.3M)(256.7M)(333.2M)(153.0M)(350.2M)(332.7M)
Retained Earnings(39.0M)(71.2M)(140.8M)(280.8M)(269.8M)(256.3M)
Accounts Payable724K2.1M8.4M4.0M4.1M2.8M
Cash187.5M268.3M341.2M161.9M358.3M202.5M
Non Current Assets Total13.1M35.8M184.0M174.7M230.4M242.0M
Non Currrent Assets Other1.5M1.6M74K324K263K249.9K
Cash And Short Term Investments193.7M271.3M438.1M379.2M532.2M271.9M
Common Stock Shares Outstanding15.9M18.8M22.2M25.5M27.8M18.0M
Liabilities And Stockholders Equity209.0M310.8M626.3M558.5M818.4M859.3M
Non Current Liabilities Total2.8M3.3M7.0M7.4M6.6M4.0M
Capital Surpluse133.2M242.0M363.3M734.5M844.7M886.9M
Other Current Assets2.2M3.8M4.2M4.6M6.7M7.0M
Other Stockholder Equity242.0M363.3M734.5M803.7M1.0B1.1B
Total Liab6.1M18.8M32.7M36.2M39.7M41.7M
Property Plant And Equipment Gross11.2M34.2M123.8M176.5M181.1M190.1M
Total Current Assets195.9M275.1M442.3M383.8M587.9M617.3M
Accumulated Other Comprehensive Income10K6K(163K)(728K)638K669.9K
Property Plant Equipment11.2M30.9M119.6M169.7M195.2M204.9M
Other Assets1.5M4.9M74K324K372.6K354.0K
Short Term Investments6.2M3.0M96.9M217.3M173.9M182.5M
Net Invested Capital202.9M292.1M593.6M522.2M778.6M401.1M
Net Working Capital192.6M259.6M416.5M354.9M554.8M304.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.